Current surveillance strategies recommended by the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD) primarily include ultrasound with or without alpha-fetoprotein (AFP) testing for high-risk populations [89, 90]. The gene discussed is AFP; the disease is liver disorder.